13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q1 2024 · Filed May 15, 2024 · Accession 0001104659-24-061747
Total Value
$197.9M
Positions
5
Other Managers
0
Confidential Omitted
No
Holdings (5)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | 4,038,842 | $93.3M | 47.16% |
| 2 | Kura Oncology, Inc. | KURA | 1,849,947 | $39.5M | 19.94% |
| 3 | Kinnate Biopharma Inc. | 49705R105 | 9,671,643 | $25.7M | 13.00% |
| 4 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $20.8M | 10.52% |
| 5 | Lyell Immunopharma, Inc. | LYEL | 8,325,000 | $18.6M | 9.38% |